Madison Vaccines, a life sciences spin-out of the University of Wisconsin, secures $8m series A.

Madison Vaccines, a biopharmaceutical spin-out from the University of Wisconsin-Madison, has closed an $8m series A ahead of planned clinical trials.

The round was led by Venture Investors, and joined by venture firm Venture Management, the State of Wisconsin Investment Board, and the University of Wisconsin-Madison’s tech transfer unit the Wisconsin Alumni Research Foundation (WARF).

Madison Vaccines is developing two promising prostate cancer vaccines, MVI-816 and MVI-118. Proceeds from the fund will be to further develop the two DNA vaccines…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?